TABLE 2.
Biological aging measures by patient, cancer, and treatment characteristics.
| AgeAccelGrim | AgeAccelPheno | DunedinPACE | ||||
|---|---|---|---|---|---|---|
| Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | |
| Female (n = 35) | 1.5 | (0.02, 3.1) | 4.4 | (1.4, 7.3) | 1.03 | (0.98, 1.08) |
| Male (n = 23) | 1.4 | (−0.9, 3.7) | −0.7 | (−3.7, 2.3) | 0.92 | (0.87, 0.98) |
| p‐Value | 0.92 | 0.02 | 0.009 | |||
| Black (n = 9) | 4.3 | (2.1, 6.6) | 3.3 | (−5.5, 12.0) | 1.02 | (0.92, 1.12) |
| White (n = 37) | −0.2 | (−1.6, 1.2) | 1.1 | (−1.4, 3.6) | 0.95 | (0.91, 1.00) |
| Other (n = 12) | 4.6 | (1.5, 7.7) | 5.5 | (0.6, 10.4) | 1.07 | (0.97, 1.18) |
| p‐Value | 0.007 | 0.26 | 0.04 | |||
| ITRS level 1, 2 (n = 14) | −0.9 | (−2.6, 0.8) | −0.2 | (−3.9, 3.5) | 0.94 | (0.87, 1.01) |
| ITRS level 3 (n = 37) | 1.7 | (0.1, 3.3) | 1.7 | (−1.0, 4.4) | 0.98 | (0.93, 1.02) |
| ITRS level 4 (n = 7) | 5.1 | (0.2, 9.9) | 10.8 | (3.7, 17.9) | 1.13 | (0.95, 1.31) |
| p‐Value | 0.02 | 0.009 | 0.01 | |||
| ≤5 years off Rx (n = 23) | 2.8 | (0.7, 4.9) | 4.8 | (0.4, 9.1) | 1.02 | (0.95, 1.09) |
| 6–10 years off Rx (n = 18) | 2.8 | (0.5, 5.2) | 1.8 | (−1.8, 5.4) | 1.03 | (0.97, 1.09) |
| >10 years off Rx (n = 17) | −1.7 | (−3.2, −0.2) | −0.3 | (−3.1, 2.5) | 0.90 | (0.84, 0.96) |
| p‐Value | 0.003 | 0.15 | 0.01 | |||
| Leukemia (n = 24) | 1.1 | (−0.6, 2.8) | 1.6 | (−1.3, 4.6) | 0.97 | (0.91, 1.04) |
| Lymphoma (n = 11) | 0.1 | (−2.5, 2.6) | 2.8 | (−3.1, 8.7) | 1.03 | (0.93, 1.13) |
| CNS tumors (n = 5) | 3.3 | (−1.7, 8.4) | 9.7 | (−4.7, 24.2) | 1.01 | (0.85, 1.17) |
| Other solid tumors (n = 18) | 2.3 | (−0.7, 5.4) | 1.0 | (−3.0, 5.0) | 0.97 | (0.90, 1.04) |
| p‐Value | 0.49 | 0.19 | 0.75 | |||
| No comorbidities (n = 36) | 0.7 | (−0.4, 1.9) | 2.1 | (−0.2, 4.5) | 0.97 | (0.93, 1.02) |
| ≥1 comorbidities (n = 22) | 2.7 | (−0.02, 5.4) | 2.7 | (−1.8, 7.2) | 1.01 | (0.94, 1.08) |
| p‐Value | 0.13 | 0.79 | 0.38 | |||
| Nonmyopenic (n = 34) | 0.2 | (−1.3, 1.7) | −0.7 | (−2.7, 1.4) | 0.93 | (0.89, 0.97) |
| Myopenic a (n = 23) | 3.3 | (1.2, 5.4) | 6.8 | (2.7, 10.9) | 1.07 | (1.00, 1.14) |
| p‐Value | 0.02 | <0.001 | <0.001 | |||
| Nonfrail (n = 31) | 1.1 | (−0.7, 2.9) | 0.2 | (−2.0, 2.3) | 0.94 | (0.90, 0.98) |
| Prefrail (n = 15) | 2.7 | (0.1, 5.3) | 4.7 | (−1.2, 10.6) | 1.05 | (0.95, 1.14) |
| Frail (n = 8) | 1.6 | (−2.2, 5.4) | 6.2 | (−2.7, 15.1) | 1.09 | (0.93, 1.24) |
| p‐Value | 0.59 | 0.08 | 0.01 | |||
Note: All p‐values report significance testing for overall difference among subgroups and were calculated using linear regression analysis. For variables with >2 categories, overall ANOVA p‐values are reported.
Abbreviations: CNS, central nervous system; ITRS, intensity treatment rating scale, version 3; Rx, treatment.
a
Myopenia defined as ≥1 standard deviation below sex‐ and age‐specific muscle mass population standards.